Velneperit

Velneperit
Clinical data
ATC code	None;
Identifiers
	IUPAC name trans-4-(tert-butylsulfonylamino)-N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexane-1-carboxamide;
CAS Number	342577-38-2;
PubChem CID	20629114;
ChemSpider	25948511;
UNII	09BQ2KJ22J;
CompTox Dashboard (EPA)	DTXSID20955806 ;
Chemical and physical data
Formula	C17H24F3N3O3S
Molar mass	407.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)S(=O)(=O)NC2CCC(CC2)C(=O)Nc1ncc(C(F)(F)F)cc1;
	InChI InChI=1S/C17H24F3N3O3S/c1-16(2,3)27(25,26)23-13-7-4-11(5-8-13)15(24)22-14-9-6-12(10-21-14)17(18,19)20/h6,9-11,13,23H,4-5,7-8H2,1-3H3,(H,21,22,24)/t11-,13-; Key:WGEWUYACXPEFPO-AULYBMBSSA-N;

Velneperit (S-2367) is a drug developed by Shionogi, which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y₅. It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development after disappointing results in Phase II clinical trials. However it was still considered a successful proof of concept of the potential of Y₅ receptor antagonists as possible anti-obesity agents in future.^[1]^[2]^[3]

References[edit]

^ Yukioka H (November 2010). "[A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 136 (5): 270–4. doi:10.1254/fpj.136.270. PMID 21079365.
^ Oda S, Manaka K, Kakiya K, Hozumi Y, Fukui Y, Omura S, et al. (April 2015). "Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist". Organic Process Research & Development. 19 (4): 531–6. doi:10.1021/acs.oprd.5b00023.
^ George M, Rajaram M, Shanmugam E (January 2014). "New and emerging drug molecules against obesity". Journal of Cardiovascular Pharmacology and Therapeutics. 19 (1): 65–76. doi:10.1177/1074248413501017. PMID 24064009. S2CID 34327832.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid21079365-1] Yukioka H (November 2010). "[A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 136 (5): 270–4. doi:10.1254/fpj.136.270. PMID 21079365.

[2] Oda S, Manaka K, Kakiya K, Hozumi Y, Fukui Y, Omura S, et al. (April 2015). "Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist". Organic Process Research & Development. 19 (4): 531–6. doi:10.1021/acs.oprd.5b00023.

[pmid24064009-3] George M, Rajaram M, Shanmugam E (January 2014). "New and emerging drug molecules against obesity". Journal of Cardiovascular Pharmacology and Therapeutics. 19 (1): 65–76. doi:10.1177/1074248413501017. PMID 24064009. S2CID 34327832.

[1]

[2]

[3]